Market Place
Sourcing Support
Galderma Shareholders Approve Annual Meeting Proposals
22 Apr 2026 //
FIRSTWORD PHARMA
Galderma Launches Alastin Regenerating Skin Nectar with TriHex+
16 Apr 2026 //
BUSINESSWIRE
Sculptra, Restylane show promise in post-weight loss care
08 Apr 2026 //
BUSINESSWIRE
Nemolizumab Shows Benefit In Pediatric AD At AAD 2026
28 Mar 2026 //
BUSINESSWIRE
Galderma Highlights Skin Solutions Data At AAD 2026
24 Mar 2026 //
BUSINESSWIRE
Galderma Receives U.S. FDA Approval for Restylane Contour
23 Mar 2026 //
BUSINESSWIRE
Galderma Releases 2026 AGM Invitation and Agenda
20 Mar 2026 //
BUSSINESSWIRE
Galderma Showcases Aesthetic Innovation At AMWC 2026
17 Mar 2026 //
BUSSINESSWIRE
Galderma Completes Successful Placement Of EUR 500 Million
11 Mar 2026 //
BUSSINESSWIRE
Galderma Buys Back Shares Worth CHF 232 Million
11 Mar 2026 //
BUSSINESSWIRE
Galderma Doubles Nemluvio Peak Sales Outlook To $4B-Plus
05 Mar 2026 //
FIERCE PHARMA
Galderma Launches Restylane Syringe in EU, US, Canada
25 Feb 2026 //
BUSINESSWIRE
Galderma Announces Appointment Of New Chief Financial Officer
16 Feb 2026 //
PHARMIWEB
Galderma Launches Restylane OBT Hyaluronic Acid Injectables
11 Feb 2026 //
BUSINESSWIRE
Galderma Addresses Menopause Skin Changes Via Global Survey
30 Jan 2026 //
BUSINESSWIRE
Galderma Updates Neuromodulator R&D Partnership Arbitration Case
21 Jan 2026 //
BUSINESSWIRE
TOXINS 2026 Highlights Advances in Galderma Neuromodulators
14 Jan 2026 //
BUSINESSWIRE
Nemluvio Eases Itch And Enhances Sleep In Atopic Dermatitis
17 Dec 2025 //
PHARMIWEB
Galderma Initiates Study On Nemolizumab For Chronic Pruritus
11 Dec 2025 //
PHARMIWEB
Galderma Welcomes Increased Equity Investment From L’Oréal
08 Dec 2025 //
BUSINESSWIRE
Galderma Secures `BBB` Rating, Positive S&P Outlook
04 Dec 2025 //
BUSINESSWIRE
Galderma Showcases Innovative Aesthetic Injectables Portfolio
17 Nov 2025 //
BUSINESSWIRE
Galderma Completes Successful Placement Of CHF 175 Million Bond
14 Nov 2025 //
BUSINESSWIRE
Galderma Achieves $3.737B In 9-Month Net Sales, Up 15% YoY
23 Oct 2025 //
BUSINESSWIRE
Galderma`s Itch Relief Claims Scratched After Sanofi Complaint
08 Oct 2025 //
FIERCE PHARMA
Galderma Debuts Cetaphil`s Skin Activator Line With Mariska
18 Sep 2025 //
BUSINESSWIRE
Galderma Leads in Dermatology with Sensitive Skin Advances
11 Sep 2025 //
PHARMAWEB
Galderma Introduces Alastin in China for Skin Regeneration
10 Sep 2025 //
BUSINESSWIRE
Galderma’s H1 Sales Hit $2.448B, Boosts Full-Year Outlook
24 Jul 2025 //
BUSINESSWIRE
Galderma Buys Back CHF 233 Million Shares in Bookbuild Offering
28 May 2025 //
BUSINESSWIRE
Galderma to Buy Back 2.4M Shares via Accelerated Offering
27 May 2025 //
BUSINESSWIRE
Galderma`s Record First Quarter Net Sales Reach 1.129 Billion USD
24 Apr 2025 //
BUSINESSWIRE
Galderma launches Alastin Skin Complex with TriHex Technology
17 Apr 2025 //
BUSINESSWIRE
Galderma Launches Sculptra® in China, Fueling Growth in Aesthetic
15 Apr 2025 //
BUSINESSWIRE
Galderma Places EUR 500M Eurobond and CHF 435M CHF Bonds
14 Mar 2025 //
BUSINESSWIRE
Galderma Leads In Weight Loss Aesthetics With New Research
30 Jan 2025 //
BUSINESSWIRE
Galderma Highlights Restylane Shaype & Relfydess Data Leadership
23 Jan 2025 //
BUSINESSWIRE
Galderma Show Injectable Aesthetic Effective For Weight-Loss Impact
14 Jan 2025 //
BUSINESSWIRE
Galderma Bets on Skin Drug to Turn Around Pharma Business
29 Nov 2024 //
WSJ
Galderma Reports $3.259B Net Sales in First Nine Months of 2024
24 Oct 2024 //
BUSINESSWIRE
Galderma Reports Record Net Sales Of $3.259B In 2024
24 Oct 2024 //
BUSINESSWIRE
ASDS 2024: Phase III READY-4 Data Shows Safety Of Relfydess™
21 Oct 2024 //
BUSINESSWIRE
Galderma Reaffirms Leadership In Dermatology With Presence At EADV 2024
17 Sep 2024 //
BUSINESSWIRE
Galderma Shows Leadership At EADV 2024
16 Sep 2024 //
BUSINESSWIRE
Amber Specialty Pharmacy To Distribute Galderma`s Prurigo Nodularis Med
12 Sep 2024 //
BUSINESSWIRE
Galderma Successfully Issued an Inaugural CHF 500 Million Bond
29 Aug 2024 //
BUSINESSWIRE
Galderma To Partner With L`Oréal In Dermatology Research
05 Aug 2024 //
BUSINESSWIRE
Galderma`s Relfydess™ Approved For Use In Europe
30 Jul 2024 //
BUSINESSWIRE
Galderma Reports 2.2B USD H1 2024 Sales, 10.8% YoY Growth
24 Jul 2024 //
BUSINESSWIRE
Galderma Granted Manufacturing License Updates for New Biologics Capabilities
23 Jul 2024 //
CONTRACT PHARMA
Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin
09 Jul 2024 //
BUSINESSWIRE
Galderma Restylane® Volyme™ Launch: Fast-Growing China Aesthetics Market
23 May 2024 //
BUSINESSWIRE
Galderma Q1 Sales Top $1B, Up 12.4% YoY
24 Apr 2024 //
BUSINESSWIRE
Galderma Announces Full Exercise of Over-Allotment Option
26 Mar 2024 //
BUSINESSWIRE
Galderma Prices IPO at CHF 53 Per Share and Will Start Trading
20 Mar 2024 //
BUSINESSWIRE
AMWC 2024: Galderma to Share New Data From Injectable Aesthetic Portfolio
19 Mar 2024 //
BUSINESSWIRE
Galderma kicks off the process for $2.6B IPO
13 Mar 2024 //
FIERCE PHARMA
Galderma Announces Intention to Float on the SIX Swiss Exchange
06 Mar 2024 //
BUSINESSWIRE
Galderma Announces Record 2023 Net Sales of Over 4 B USD
29 Feb 2024 //
BUSINESSWIRE
Galderma`s net sales top $4 billion in 2023 ahead of potential IPO
28 Feb 2024 //
REUTERS
